ClinicalTrials.gg
CompletedNCT05405985Updated Jan 3, 2025Results posted

Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

A Phase 1 interventional study of Nemolizumab and Nemolizumab in Healthy Volunteers, sponsored by Galderma R&D. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
8th of 14
192 · median 209
Started
2022
the only one that year
Phase 1
Only one
of the 14
Registered
11th of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 8th largest by enrollment, is the only one that started in 2022, is the only one in phase 1, and was the 11th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult subjects.

03

Conditions studied

  • Healthy Volunteers

Browse trials for

Keywords

  • Auto-Injector (AI)
  • Dual-Chamber Syringe (DCS)
  • Atopic dermatitis (AD)
  • Prurigo nodularis (PN)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 18 to 65 years at screening visit.
  • Body weight >= 45 kilogram (kg) and between >=18.0 and \<30.0 kilograms per meter squared (kg/m\^2) at both screening and baseline visits.
  • Medically healthy with normal clinical status as judged by the investigator based on medical history, physical examination, and clinical laboratory tests.
  • Willing to abstain from all prescription medications during the study, (defined hereafter as after signing of form), except to treat AEs and , and as permitted under Exclusion 2. Limited use of non-prescription medications/supplements that were not believed to affect participant's safety or the overall results of the study might be permitted at the discretion of investigator.
  • Female participants of (i.e., fertile, after menarche and, until becoming unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the study drug injection, or to use an adequate and approved method of contraception throughout the study and for 12 weeks after the study drug injection. Males are not required to use contraception, and there is no restriction on sperm donation.
  • Female participants of non-childbearing potential must meet one of these criteria; absence of menstrual bleeding for 1 year before the screening visit with no other medical reason, confirmed with follicle-stimulating hormone (FSH) level in the postmenopausal range or documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before the study.
  • Willing and able to comply with all of the time commitments and procedural requirements of the clinical study protocol.
  • Understood and signed an informed consent form before any procedure(s) are performed.

Exclusion criteria

Exclusion Criteria:

  • History of (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, e.g., monoclonal antibody) or to any of the study drug .
  • Cutaneous infection within 1 week before the baseline visit or any infection requiring treatment with oral, parental antibodies, antivirals, antiparasitics, or antifungals within 2 weeks before the baseline visit.
  • Any confirmed or suspected coronavirus disease (COVID-19) infection within 2 weeks before screening or baseline visit.
  • Positive serology results ( surface antigen [HBsAg] or hepatitis B core antibody [HBcAb], [HCV] antibody with positive HCV RNA, or [HIV] antibody) at the screening visit.
  • Known or suspected or unusually frequent, recurrent, severe, or prolonged infections as per investigator judgment.
  • History of lymphoproliferative disease or history of of any organ system within last 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ (Bowen's disease), or carcinomas in situ of the cervix that have been treated and have no clinical evidence of recurrence in the last 12 weeks before baseline visit, or actinic keratoses that have been treated.
  • Previous treatment with Nemolizumab.
  • Known active or untreated latent tuberculosis infection.
  • Any condition that may interfere with study assessments (e.g., poor venous access or needle phobia).
  • Having received a live-attenuated or non- within 4 weeks before the baseline visit or are expected to be vaccinated during the study or during the 12 weeks after the last study drug injection, except for non-live seasonal vaccinations, COVID-19 and /or emergency vaccinations.
  • Planned or expected major surgical procedure during the clinical study.
  • Pregnant women, breastfeeding women, or women planning a pregnancy during the study or 12 weeks after the study drug injection.
  • Participating or participated in any other study with an drug or device within the past 8 weeks before the screening visit, or is in an exclusion period from a previous study.
  • Participants who have donated ≥ 500 mL of blood in the last 3 months before doing.
  • History of alcohol or substance abuse within 6 months of the screening visit.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Nemolizumab With Auto-Injector (AI)

    Participants received a 60 milligrams (mg) dose of nemolizumab as 2 successive subcutaneous (SC) injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 centimeters \[cm\]) apart with AI on Day 0 (injection day).

    Drug: Nemolizumab

  • Experimental
    Nemolizumab With Dual Chamber Syringe (DCS)

    Participants received a 60-mg dose of nemolizumab as 2 successive subcutaneous injections of 30 mg nemolizumab at either of the same location i.e., abdomen, front upper thigh, or outer upper arm and on the same side with injection sites at least 1 inch (2.5 cm) apart with DCS on Day 0 (injection day).

    Drug: Nemolizumab

Interventions

  • Nemolizumab with Auto-Injector (AI).

  • Nemolizumab with Dual-Chamber Syringe (DCS).

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Nemolizumab

    Cmax was defined as the observed maximum serum concentration of nemolizumab. Cmax was used to measure the rate of absorption of nemolizumab.

    Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose

  2. Area Under Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Nemolizumab

    AUC0-inf was defined as area under the plasma concentration-time curve from time 0 to infinity according to the equation: AUC0-inf = AUClast + Clast/λz; where λz = slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale; and Clast = last measurable drug concentration.

    Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose

Secondary outcomes

  1. Area Under the Concentration-time Curve Over the Specified Interval (AUC0-4 Weeks) of Nemolizumab

    AUC0-4 weeks was defined as area under the concentration-time curve from time 0 to 4 weeks after study drug administration calculated with the linear trapezoidal method.

    Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22 and 29 post-dose

  2. Area Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC0-last) of Nemolizumab

    AUC0-last was defined as area under the concentration-time curve from administration to the last observed concentration time t, calculated with the linear trapezoidal method.

    Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose

  3. Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab

    Tmax was defined as the time taken to reach the maximum observed serum concentration.

    Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose

  4. Half-life (t1/2) of Nemolizumab

    t1/2 is defined as time required for the concentration of the drug to reach half of its original value.

    Time frame: Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose

  5. Number of Participants With Positive Anti-drug Antibodies (ADA) Response Against Nemolizumab

    ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.

    Time frame: Pre-dose, Day 29 and 85 post-dose

07

Results

Posted Jan 3, 2025

Participant flow

The study was conducted at 2 sites in United States from 11 August 2022 to 08 December 2022.

Participant flow — Overall Study
MilestoneNemolizumab With Auto-Injector (AI)Nemolizumab With Dual Chamber Syringe (DCS)
Started9696
Completed9596
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Nemolizumab

Cmax was defined as the observed maximum serum concentration of nemolizumab. Cmax was used to measure the rate of absorption of nemolizumab.

Time frame:
Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Maximum Observed Plasma Concentration (Cmax) of Nemolizumab
micrograms per milliliter (mcg/mL)Nemolizumab With AINemolizumab With DCS
Maximum Observed Plasma Concentration (Cmax) of Nemolizumab8.00 ± 2.347.51 ± 2.31
PrimaryArea Under Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Nemolizumab

AUC0-inf was defined as area under the plasma concentration-time curve from time 0 to infinity according to the equation: AUC0-inf = AUClast + Clast/λz; where λz = slope of the regression line of the terminal phase of the plasma concentration versus time curve, in semi-logarithmic scale; and Clast = last measurable drug concentration.

Time frame:
Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Reported as:
Mean · micrograms*day per milliliter
Area Under Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Nemolizumab
micrograms*day per milliliterNemolizumab With AINemolizumab With DCS
Area Under Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Nemolizumab270 ± 85.8279 ± 89.7
SecondaryArea Under the Concentration-time Curve Over the Specified Interval (AUC0-4 Weeks) of Nemolizumab

AUC0-4 weeks was defined as area under the concentration-time curve from time 0 to 4 weeks after study drug administration calculated with the linear trapezoidal method.

Time frame:
Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22 and 29 post-dose
Reported as:
Mean · micrograms*day per milliliter
Area Under the Concentration-time Curve Over the Specified Interval (AUC0-4 Weeks) of Nemolizumab
micrograms*day per milliliterNemolizumab With AINemolizumab With DCS
Area Under the Concentration-time Curve Over the Specified Interval (AUC0-4 Weeks) of Nemolizumab157 ± 37.9155 ± 39.8
SecondaryArea Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC0-last) of Nemolizumab

AUC0-last was defined as area under the concentration-time curve from administration to the last observed concentration time t, calculated with the linear trapezoidal method.

Time frame:
Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Reported as:
Mean · micrograms*day per milliliter
Area Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC0-last) of Nemolizumab
micrograms*day per milliliterNemolizumab With AINemolizumab With DCS
Area Under Concentration-time Curve From Administration to the Last Observed Concentration Time t (AUC0-last) of Nemolizumab250 ± 73.6260 ± 75.4
SecondaryTime to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab

Tmax was defined as the time taken to reach the maximum observed serum concentration.

Time frame:
Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Reported as:
Median · days
Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab
daysNemolizumab With AINemolizumab With DCS
Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab4.99 (1.00 to 21.99)5.99 (1.00 to 22.00)
SecondaryHalf-life (t1/2) of Nemolizumab

t1/2 is defined as time required for the concentration of the drug to reach half of its original value.

Time frame:
Pre-dose, 12 hours, 24 hours, Days 3, 4, 5, 6, 7, 8, 9, 10, 11, 15, 22, 29, 36, 43, 50, 57, 71, and 85 post-dose
Reported as:
Mean · days
Half-life (t1/2) of Nemolizumab
daysNemolizumab With AINemolizumab With DCS
Half-life (t1/2) of Nemolizumab18.0 ± 5.9118.5 ± 4.52
SecondaryNumber of Participants With Positive Anti-drug Antibodies (ADA) Response Against Nemolizumab

ADA positive was defined as a sample that was evaluated as positive in both the ADA screening and confirmatory assays. ADA positive participants was defined as participants who had at least 1 positive ADA result.

Time frame:
Pre-dose, Day 29 and 85 post-dose
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-drug Antibodies (ADA) Response Against Nemolizumab
ParticipantsNemolizumab With AINemolizumab With DCS
Pre-dose: ADA postive68
Day 29: ADA positive24
Day 85: ADA positive28

Adverse events

Collected over From Baseline up to Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nemolizumab With AI0/96 (0%)0/96 (0%)41/96 (42.7%)
Nemolizumab With DCS0/96 (0%)0/96 (0%)54/96 (56.3%)
Most frequent other events
Showing 10 of 94
Most frequent other events
EventNemolizumab With AINemolizumab With DCS
HeadacheNervous system disorders8/9622/96
Weight increasedInvestigations7/965/96
Back painMusculoskeletal and connective tissue disorders1/965/96
PruritusSkin and subcutaneous tissue disorders1/965/96
NauseaGastrointestinal disorders2/964/96
PapuleSkin and subcutaneous tissue disorders1/964/96
Viral infectionInfections and infestations0/963/96
ArthralgiaMusculoskeletal and connective tissue disorders1/963/96
ErythemaSkin and subcutaneous tissue disorders3/960/96
PalpitationsCardiac disorders0/962/96

Baseline characteristics

Analysis was performed on safety population that included all randomized participants who received the single dose of nemolizumab and was the primary population for all safety data.

Age, Continuous
Age, Continuous(years)Nemolizumab With AINemolizumab With DCSTotal
Mean40.9 ± 11.7142.1 ± 12.5241.5 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)Nemolizumab With AINemolizumab With DCSTotal
Female5562117
Male413475
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nemolizumab With AINemolizumab With DCSTotal
Hispanic or Latino5351104
Not Hispanic or Latino434588
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nemolizumab With AINemolizumab With DCSTotal
American Indian or Alaska Native112
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American9817
White8280162
More than one race459
Unknown or Not Reported000
08

Study locations

2 sites
  • Galderma Investigational Site 7024
    Tempe, Arizona 85283, United States
  • Galderma Investigational Site 7023
    Lincoln, Nebraska 68502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Nov 2022, 3 months.

Results were first posted in Jan 2025, 2 years 1 month after primary completion.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 3 months is below that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2022
First posted
Jun 6, 2022
StartActual
Aug 11, 2022
Primary completionActual
Nov 11, 2022
CompletionActual
Dec 8, 2022
Results first posted
Jan 3, 2025
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05405985
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Aug 11, 2022
Primary completion
Nov 11, 2022
Completion
Dec 8, 2022
Results posted
Jan 3, 2025
Last update
Jan 3, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion